At a glance: The "Wolverine stack" pairs two research peptides, BPC-157 and TB-500, marketed for injury recovery. Each has some animal data, but no controlled human study has shown either one heals injuries, and the combination has never been tested in people. Neither is FDA-approved, both are banned in sport, and FDA's own reviewers recommended against allowing either in compounding.
What is the BPC-157 + TB-500 stack?
It is a combination of two separate lab-made peptides, sold either as two vials or as a pre-mixed blend. "Wolverine stack" is a marketing nickname, after the comic-book character who heals rapidly. It is not a standardized product, so ratios and contents vary between sellers.
- BPC-157 is a 15-amino-acid peptide derived from a protective protein in gastric juice, studied mostly in rats for tendon, muscle and gut injuries.
- TB-500 is a short synthetic fragment of thymosin beta-4, a natural protein involved in cell movement and tissue repair. The version FDA reviewed is seven amino acids long (residues 17-23 of thymosin beta-4, Ac-LKKTETQ).
"TB-500" on a label does not always mean the same thing. Full-length thymosin beta-4, shorter fragments, and acetate or free-base forms are different substances and are not interchangeable.
Why are the two paired?
The pairing is based on the idea that the two work in complementary ways, not on any study of the combination:
| BPC-157 | TB-500 / thymosin beta-4 | |
|---|---|---|
| Proposed role | Local, targeted repair | Whole-body tissue remodeling |
| Mechanisms in lab and animal work | New blood vessel growth, tendon cell organization, nitric oxide and growth hormone receptor signaling | Cell migration via actin binding, reduced inflammation, tissue remodeling |
| Main research models | Rat tendon, muscle and gut injuries | Mouse wound and heart-injury models (full-length thymosin beta-4) |
| Human evidence for healing | A two-person pilot report; one trial recruiting | None for TB-500 |
What the research shows so far
- BPC-157: many rat studies report faster healing of tendon, ligament, muscle and gut injuries, mostly from a small number of research groups. Human data are limited to a two-person IV pilot and a phase 2 hamstring trial that has not reported results.
- Full-length thymosin beta-4: promoted wound healing and heart-cell survival in mice, and in a small 18-patient phase 3 trial, thymosin beta-4 eye drops (RGN-259) showed a trend toward faster healing of a rare corneal condition that narrowly missed its main statistical goal. These results apply to the full protein, not the TB-500 fragment.
- TB-500 itself: FDA's 2026 review found no human pharmacokinetic, efficacy or safety studies. In the one lab wound test it identified, TB-500 did not significantly speed wound closure. In horses it was cleared from the blood within hours.
- The combination: a 2026 rat Achilles-tendon study found that BPC-157 and TB-500 together added no benefit over either alone. No study in people has tested the pair.
FDA noted that the wound-healing studies cited to support TB-500 actually tested a slightly different, non-acetylated sequence in mice, not TB-500 itself.
Why it gets attention
- Sports and injury culture: promoted for tendons, ligaments, muscle tears and surgical recovery
- The "two is better than one" appeal of combining a local and a whole-body peptide
- Before-and-after stories online, which can't separate the peptides from rest, rehab and natural healing
- The July 2026 FDA advisory vote, which put both compounds in the news
How it is given
Products are typically sold for injection under the skin, as separate vials or a pre-mixed blend. A blend fixes the ratio between the two, so changing the amount of one changes the other. There is no established human dose for either peptide or the combination, and this page does not provide dosing guidance.
What about side effects?
Human safety is essentially unknown for both peptides. Reported problems include injection-site redness, warmth and swelling. Fever, spreading redness or worsening pain can signal infection, which is a real risk with non-sterile products.
- Masking injuries: a new injury may need imaging or examination to rule out a fracture, clot, infection or torn structure before anything else.
- Blood vessel and growth signaling: both peptides are linked to tissue growth pathways. People with a history of cancer, blood vessel disorders, or who take blood thinners face unstudied risks.
- Immune reactions: FDA considers injectable peptides a significant immunogenicity risk, made worse by aggregates and impurities.
- Product quality: FDA found that available certificates of analysis for TB-500 did not test for aggregates, endotoxins or identity. Blends also need compatibility, sterility and stability data that sellers rarely provide.
- Pregnancy and breastfeeding: safety not established.
Regulatory status
Neither peptide is an FDA-approved drug. In July 2026 an FDA advisory committee voted 8 to 6, with 1 abstention, to recommend each of them for the list of substances compounding pharmacies may use.
- FDA's own reviewers recommended against both, citing poor characterization, no evidence of effectiveness and unknown human safety. For TB-500, FDA said it was particularly concerned about the complete absence of human data.
- The vote is advisory and non-binding. Nothing has been added to the list, and doing so requires a formal rulemaking.
- Even if added, each peptide would be compounded individually. Pre-mixed blends sold online remain unregulated.
- Both are on the World Anti-Doping Agency's prohibited list. TB-500 has been detected in doping cases in human sport and horse racing.
The bottom line
The Wolverine stack combines one peptide with encouraging animal data (BPC-157) and one with almost no direct data (TB-500), on the theory that they complement each other. That theory has never been tested. With no human evidence for the combination, unknown safety and inconsistent products, claims of faster healing are marketing rather than science. Anyone recovering from an injury should work with a licensed clinician or physical therapist on approaches with proven benefit.
Frequently asked questions
What is BPC-157 + TB-500 (blend)?
Two separate peptides, BPC-157 and TB-500, sold together in one vial. Each has its own page on this site.
How is BPC-157 + TB-500 (blend) taken?
No established route.
Is BPC-157 + TB-500 (blend) FDA approved?
Not approved; both parts are on WADA’s prohibited list.
That means no regulator has reviewed its safety, effectiveness or manufacturing quality for this use.
What has research shown about BPC-157 + TB-500 (blend)?
- No studies have tested this combination. Research on each peptide is summarized on its own page.
What side effects have been reported?
- Unknown for the combination
Serious or less common risks are listed in the Side Effects section above.
What is still unknown about its safety?
Most of it. BPC-157 + TB-500 (blend) has not been through the trials that establish long-term safety in people, and products sold online are made by unregulated labs. Independent testing of online peptides has repeatedly found contents that do not match the label.
References
- Rite Aid: BPC-157 + TB-500, evidence, schedules and safety. View source
- FDA: evaluation of TB-500 and TB-500 acetate for the 503A bulks list (2026). View source
- FDA: evaluation of BPC-157-related bulk drug substances (2026). View source
- Sosne G, et al. 0.1% RGN-259 (thymosin beta-4) ophthalmic solution in neurotrophic keratopathy: randomized, placebo-controlled phase III trial. 2022. View source
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing. Journal of Applied Physiology. 2011. View source
- AJMC: FDA panel backs 6 peptides for compounding (July 2026). View source
- BSCG: TB-500 status, risks and bans in sport and the military. View source